Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of

#### the Securities Exchange Act of 1934
Filed by the Registrant x

Filed by a party other than the Registrant o

Check the appropriate box:

| o |     | Preliminary Proxy Statement                                                     |
| o |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x |     | Definitive Proxy Statement                                                      |
| o |     | Definitive Additional Materials                                                 |
| o |     | Soliciting Material under §240.14a-12                                           |

#### WHITEHAWK THERAPEUTICS, INC.
<div align='center'>(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| x |     | No fee required.                                                                                     |
| o |     | Fee paid previously with preliminary materials.                                                      |
| o |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

April 28, 2025

To the Stockholders of Whitehawk Therapeutics, Inc.:

You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Whitehawk Therapeutics, Inc. (the “Company”), which will be held online on Wednesday, June 11, 2025 at 10:00 a.m. Pacific Time via webcast at www.virtualshareholdermeeting.com/WHWK2025 . The Annual Meeting will be a completely virtual meeting which will be conducted via live webcast.

Details regarding admission to the meeting and the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.

At this Annual Meeting, the agenda includes:

1. To elect three Class II directors to serve on the Company’s board of directors until the Company’s 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal;

2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the “